Skip directly to site content Skip directly to page options Skip directly to A-Z link


Centers for Disease Control and Prevention. CDC twenty four seven. Saving Lives, Protecting People
														Search
		×
			NIOSH
			NIOSH
				All CDC
				Submit
			For a full list of topics:A-Z Index
			Advanced Search
		Advanced Search


The National Institute for Occupational Safety and Health (NIOSH)


Facebook
        Twitter
        LinkedIn
        Syndicate





MALATHION								Related Pages
										*OSHA comments from the January 19, 1989 Final Rule on Air Contaminants Project extracted from 54FR2332 et. seq. This rule was remanded by the U.S. Circuit Court of Appeals and the limits are not currently in force.*
**CAS:** 121-75-5; **Chemical Formula:** C10H19O6PS2
OSHA formerly had a 15-mg/m3 total particulate limit for malathion, with a skin notation; the ACGIH TLV for this substance is 10 mg/m3 as a TWA, also with a skin notation, and the NIOSH REL is 15 mg/m3. The proposed PEL was 10 mg/m3 (total particulate), with a skin notation. The final rule establishes a 10 mg/m3 TWA limit for total malathion particulate and includes a skin notation; the 5-mg/m3 TWA limit for the respirable fraction is retained. NIOSH (Ex. 8-47, Table N4) concurs with the selection of these limits. Malathion is a noncombustible, yellow to deep brown liquid with a skunk-like odor.
Malathion is a widely used organophosphorus insecticide having a relatively low level of toxicity; some authors have determined that malathion is approximately 1/100th as toxic as parathion (Johnson, Fletcher, Nolan, and Cassaday 1952/ Ex. 1-149). Rats fed malathion at a concentration of 100 ppm for two years exhibited no toxic effects (Hazleton and Holland 1953/Ex. 1-126). Several occupational and research exposures involving scientists or human volunteers produced no changes in blood cholinesterase or other effects (Rider, Mueller, Swader et al. 1959/Ex. 1-189; Hayes, Mattson, Short, and Witter 1960/Ex. 1-90; Culver, Caplan, and Batchelor 1956/Ex. 1-177). Fatalities have been reported in the Japanese and Indian literature, but these deaths have always involved extremely high doses of malathion (Chabra 1970/Ex. 1-151; Horiguchi 1973/Ex. 1-221). The symptoms of malathion overexposure include headache, lacrimation, vomiting, tremors, and convulsions.
The Agency received, in addition to NIOSH’s comment, two record comments on malathion. ConAgra, Inc. (Ex. 3-635) questioned the classification of this substance as a nuisance dust “since most malathion-containing pesticides are liquids and are available over the counter for public use in retail stores” (Ex. 3-635, p. 2). OSHA points out that this health effects category includes all particulates (i.e., can include aerosols and mists generated by the handling of liquid materials).
Another commenter, Lawrence H. Hecker, Director of Corporate Industrial Hygiene and Toxicology for Abbott Laboratories, questioned the need for a skin notation for a substance with a dermal LD(50) of 200 mg/kg or less in animal tests when there was no evidence of systemic effects in humans as a result of skin contact (Ex. 3-678, p. 3). Dr. Hecker stated that this 200-mg/kg cutoff would be consistent with OSHA’s Hazard Communication Standard (29 CFR 1910.1200). OSHA agrees with Dr. Hecker that a consistent policy in regard to skin notations is appropriate but does not agree that the 200-mg/kg level is an appropriate cutoff point. The Agency finds that a dermal LD(50) in rabbits of 1000 mg/kg is a better indicator of dermal toxicity; this is the Hazard Communication Standard’s upper cutoff for a toxic, rather than highly toxic, substance administered by the dermal route (see Section VI.C.18 of this preamble for a discussion of OSHA’s reasoning on this issue). In addition, OSHA believes that evidence that a substance has caused systemic toxicity in humans exposed via the dermal route is sufficient reason to retain a skin notation; in the case of malathion, OSHA has received reports of exposed workers whose blood cholinesterase levels were reduced after dermal exposure to this substance. OSHA is therefore retaining the skin notation for malathion in the final rule.
In the final rule, OSHA is establishing PELs of 10 mg/m3 TWA (total particulate) and 5 mg/m3 TWA (respirable particulate) with a skin notation. The Agency finds that exposure to malathion poses a significant risk of material health impairment in the form of cholinesterase inhibition.
										
							
								Page last reviewed:  September 28, 2011						Content source:  	National Institute for Occupational Safety and Health NIOSH
1988 OSHA PEL Project Documentation
Index of Chemical Names
Index of CAS Numbers Follow NIOSH Facebook
Pinterest
Twitter
YouTube
 NIOSH Homepage NIOSH A-Z
Workplace Safety & Health Topics
Publications and Products
Programs
Contact NIOSH


About CDC
					Contact Us
					800-232-4636
 Facebook Twitter Instagram LinkedIn Youtube Pinterest Snapchat
 CONTACT CDC
				Contact Us
							Call 800-232-4636
							Email Us
			ABOUT CDC
				About CDC
							Jobs
							Funding
			POLICIES
				Accessibility
							External Links
							Privacy
							Policies
							No Fear Act
							FOIA
							OIG
							Nondiscrimination
							Vulnerability Disclosure Policy
			CONNECT WITH US
				Facebook
								Twitter
								Instagram
								LinkedIn
							Youtube
								Pinterest
								Snapchat
								Email
			LANGUAGES
				Español
							繁體中文
							Tiếng Việt
							한국어
							Tagalog
							Русский
							العربية
							Kreyòl Ayisyen
							Français
							Polski
							Português
							Italiano
							Deutsch
							日本語
							فارسی
							English


U.S. Department of Health & Human Services
			Accessibility
			External Links
			Privacy
			Policies
			No Fear Act
			FOIA
			Nondiscrimination
			OIG
			Vulnerability Disclosure Policy
			USA.gov


Exit Notification / Disclaimer Policy Close
 Links with this icon  indicate that you are leaving the CDC website. The Centers for Disease Control and Prevention (CDC) cannot attest to the accuracy of a non-federal website.
				Linking to a non-federal website does not constitute an endorsement by CDC or any of its employees of the sponsors or the information and products presented on the website.
				You will be subject to the destination website's privacy policy when you follow the link.
				CDC is not responsible for Section 508 compliance (accessibility) on other federal or private website. Website Disclaimers
 Cancel Continue